A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals

English version České info

A protective vaccine against HIV-1 will likely require the elicitation of a broadly neutralizing antibody (bNAb) response. Although the development of an immunogen that elicits such antibodies remains elusive, a proportion of HIV-1 infected individuals evolve broadly neutralizing serum responses over time, demonstrating that the human immune system can recognize and generate NAbs to conserved epitopes on the virus. Understanding the specificities that mediate broad neutralization will provide insight into which epitopes should be targeted for immunogen design and aid in the isolation of broadly neutralizing monoclonal antibodies from these donors. Here, we have used a number of new and established technologies to map the bNAb specificities in the sera of 19 donors who exhibit among the most potent cross-clade serum neutralizing activities observed to date. The results suggest that broad and potent serum neutralization arises in most donors through a limited number of specificities (1–2 per donor). The major targets recognized are an epitope defined by the bNAbs PG9 and PG16 that is associated with conserved regions of the V1, V2 and V3 loops, an epitope overlapping the CD4 binding site and possibly the coreceptor binding site, an epitope sensitive to a loss of the glycan at N332 and distinct from that recognized by the bNAb 2G12 and an epitope sensitive to an I165A substitution. In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera.

Vyšlo v časopise: A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals. PLoS Pathog 6(8): e32767. doi:10.1371/journal.ppat.1001028
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001028

Souhrn

Zdroje

1. ZinkernagelRM

2003 On natural and artificial vaccinations. Annu Rev Immunol 21 515 546

2. PlotkinSA

2001 Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20 63 75

3. AmannaIJ

SlifkaMK

2009 Wanted, dead or alive: new viral vaccines. Antiviral Res 84 119 130

4. AmannaIJ

MessaoudiI

SlifkaMK

2008 Protective immunity following vaccination: how is it defined? Hum Vaccin 4 316 319

5. ParrenPW

MarxPA

HessellAJ

LuckayA

HarouseJ

2001 Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75 8340 8347

6. MascolaJR

StieglerG

VanCottTC

KatingerH

CarpenterCB

2000 Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 207 210

7. MascolaJR

LewisMG

StieglerG

HarrisD

VanCottTC

1999 Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73 4009 4018

8. HessellAJ

RakaszEG

TehraniDM

HuberM

WeisgrauKL

2009 Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10, Directed Against the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Membrane Proximal External Region (MPER), Protect Against SHIVBa-L Mucosal Challenge. J Virol

9. HessellAJ

RakaszEG

PoignardP

HangartnerL

LanducciG

2009 Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5 e1000433

10. HessellAJ

PoignardP

HunterM

HangartnerL

TehraniDM

2009 Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15 951 954

11. VeazeyRS

ShattockRJ

PopeM

KirijanJC

JonesJ

2003 Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9 343 346

12. MascolaJR

2003 Defining the protective antibody response for HIV-1. Curr Mol Med 3 209 216

13. MascolaJR

2002 Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20 1922 1925

14. WalkerBD

BurtonDR

2008 Toward an AIDS vaccine. Science 320 760 764

15. SimekMD

RidaW

PriddyFH

PungP

CarrowE

2009 HIV-1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified Using a High Throughput Neutralization Assay Together with an Analytical Selection Algorithm. J Virol

16. SatherDN

ArmannJ

ChingLK

MavrantoniA

SellhornG

2009 Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 757 769

17. LiY

SvehlaK

LouderMK

WycuffD

PhogatS

2009 Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83 1045 1059

18. StamatatosL

MorrisL

BurtonDR

MascolaJR

2009 Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15 866 870

19. MascolaJR

MontefioriDC

The role of antibodies in HIV vaccines. Annu Rev Immunol 28 413 444

20. WalkerLM

BurtonDR

Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol

21. DouekDC

KwongPD

NabelGJ

2006 The rational design of an AIDS vaccine. Cell 124 677 681

22. BinleyJM

LybargerEA

CrooksET

SeamanMS

GrayE

2008 Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 11651 11668

23. GrayES

MadigaMC

MoorePL

MlisanaK

Abdool KarimSS

2009 Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 83 11265 11274

24. DhillonAK

DonnersH

PantophletR

JohnsonWE

DeckerJM

2007 Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81 6548 6562

25. LiY

MiguelesSA

WelcherB

SvehlaK

PhogatA

2007 Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13 1032 1034

26. WalkerLM

PhogatSK

Chan-HuiPY

WagnerD

PhungP

2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

27. ScheidJF

MouquetH

FeldhahnN

SeamanMS

VelinzonK

2009 Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 636 640

28. DosenovicP

ChakrabartiB

SoldemoM

DouagiI

ForsellMN

2009 Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol 183 3373 3382

29. MornerA

DouagiI

ForsellMN

SundlingC

DosenovicP

2009 Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol 83 540 551

30. Doria-RoseNA

KleinRM

ManionMM

O'DellS

PhogatA

2009 Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83 188 199

31. LiY

SvehlaK

MathyNL

VossG

MascolaJR

2006 Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 80 1414 1426

32. GrundnerC

LiY

LouderM

MascolaJ

YangX

2005 Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 33 46

33. YangX

LeeJ

MahonyEM

KwongPD

WyattR

2002 Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76 4634 4642

34. CortiD

LangedijkJP

HinzA

SeamanMS

VanzettaF

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5 e8805

35. MooreJP

SodroskiJ

1996 Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70 1863 1872

36. ScanlanCN

PantophletR

WormaldMR

Ollmann SaphireE

StanfieldR

2002 The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol 76 7306 7321

37. GornyMK

StamatatosL

VolskyB

ReveszK

WilliamsC

2005 Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79 5232 5237

38. RobinsonJE

FrancoK

ElliottDH

MaherMJ

ReynaA

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol

39. CalareseDA

ScanlanCN

ZwickMB

DeechongkitS

MimuraY

2003 Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 2065 2071

40. LuallenRJ

FuH

Agrawal-GamseC

MboudjekaI

HuangW

2009 A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 83 4861 4870

41. StamatatosL

MorrisL

BurtonDR

MascolaJR

2009 Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med

42. GrayES

TaylorN

WycuffD

MoorePL

TomarasGD

2009 Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83 8925 8937

43. BurtonDR

PyatiJ

KoduriR

SharpSJ

ThorntonGB

1994 Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 1024 1027

44. BraibantM

BrunetS

CostagliolaD

RouziouxC

AgutH

2006 Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20 1923 1930

45. SchiefWR

BanYE

StamatatosL

2009 Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 4 431 440

46. ScanlanCN

RitchieGE

BaruahK

CrispinM

HarveyDJ

2007 Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 372 16 22

47. HoDD

McKeatingJA

LiXL

MoudgilT

DaarES

1991 Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 65 489 493

48. TrkolaA

PomalesAB

YuanH

KorberB

MaddonPJ

1995 Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69 6609 6617

49. WyattR

MooreJ

AccolaM

DesjardinE

RobinsonJ

1995 Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 69 5723 5733

50. PantophletR

Aguilar-SinoRO

WrinT

CavaciniLA

BurtonDR

2007 Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364 441 453

51. MoulardM

PhogatSK

ShuY

LabrijnAF

XiaoX

2002 Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 99 6913 6918

52. StieglerG

KunertR

PurtscherM

WolbankS

VoglauerR

2001 A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17 1757 1765

53. NelsonJD

BrunelFM

JensenR

CrooksET

CardosoRM

2007 An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81 4033 4043

54. LiM

GaoF

MascolaJR

StamatatosL

PolonisVR

2005 Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 10108 10125